We present the current results of a systematic review of studies about the use of therapeutic drug monitoring (TDM) for methylphenidate, amphetamine, atomoxetine and guanfacine in the treatment of ADHD and the calculation of the respective preliminary therapeutic reference ranges in children and adolescents.
No takes yet. Share an insight, caveat, or question.
Hagenkötter et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: